Allergy Therapeutics Stumped As Birch Product Fails At Phase III
Executive Summary
A strong immunological response to the PQ Birch vaccine did not translate into any appreciable reduction in symptoms in the Phase III trial, leaving the UK firm perplexed, and its share price southwards.
You may also be interested in...
Anergis And Virometix Collaborate On Fast-Acting Allergy Immunotherapy
An ultra-fast-acting allergy immunotherapy to induce tolerance to house dust mites is being sought in a collaboration between two Swiss biotechs, Anergis and Virometix.
Allergy Therapeutics: We’ve Learned From Our ‘Birch Mistakes’
Allergy Therapeutics says it has learned lessons from its failed Phase III birch pollen allergy trial and is applying those to its pivotal grass Phase III study.
Phase III Beckons For A Short-Course Seasonal Allergic Rhinitis Jab
A marketing approval for a seasonal allergic rhinitis vaccine from Allergy Therapeutics has moved nearer with positive top-line Phase II results that define the dose to be used in a Phase III study.